#### Edgar Filing: BELANOFF JOSEPH K - Form 4

BELANOFF	JOSEPH K									
Form 4										
February 12,	2019									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL	
Washington, D.									OMB Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box if no longer STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 Section 17(a) of the Public Utility Holding Company Act of 1935 or Sect 30(h) of the Investment Company Act of 1940						nge Act of 1934, of 1935 or Sectio	January 31 2009 Estimated average burden hours per response 0.9			
(Print or Type I	Responses)									
1. Name and Address of Reporting Person <u>*</u> BELANOFF JOSEPH K			2. Issuer Name <b>and</b> Ticker or Trading Symbol CORCEPT THERAPEUTICS INC [CORT]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
INCORPOR	(First) EPT THERAPE ATED, 149 WEALTH DRIV			of Earliest Tr Day/Year) 2019	ransaction			X Director X Officer (give below) Chief ]		
			ed(Month/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
MENLO FA	<b>KK</b> , CA 94023							Person		
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securi	ities A	cquired, Disposed of	f, or Beneficia	lly Owned
	2. Transaction Date (Month/Day/Year)		Date, if	Code (Instr. 8)	Disposed (Instr. 3, 4	(A) or of (D) 4 and 5 (A) or	)	SecuritiesHBeneficially(Owned(	6. Ownership Form: Direct D) or Indirect I) Instr. 4)	Indirect
				Code V		(D)				
Reminder: Rep	ort on a separate lin	e for each cl	ass of sec	urities benef	ficially ow	ned dir	ectly o	or indirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: BELANOFF JOSEPH K - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transact Code (Instr. 8)	5. Number of iorDerivative Securities Acquired (A) or Disposed of (D (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	7 (A) (D	) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 11.35	02/08/2019		А	475,000	<u>(1)</u>	02/07/2029	Common Stock	475,000

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
		10% Owner	Officer	Other		
BELANOFF JOSEPH K C/O CORCEPT THERAPEUTICS INCORPORATED 149 COMMONWEALTH DRIVE MENLO PARK, CA 94025	Х		Chief Executive Officer			
Signaturos						

### **Signatures**

/s/ Joseph K. Belanoff	02/12/2019		
<u>**</u> Signature of Reporting Person	Date		

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly(1) anniversary of February 8, 2019, so that the total number of shares subject to this option becomes fully vested and exercisable on February 8, 2023.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.